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INTRODUKSJON: Docetaxel (DOC) er et potent kjemoterapeutisk legemiddel, men som har 
flere begrensninger inkludert dårlig løselighet. Dagens tilgjengelige formulering med DOC 
begrenses av rapporterte alvorlige bivirkninger som enten skyldes legemidlet i seg selv eller 
hjelpestoffene brukt i formuleringen. Nanomedisin har blitt brukt for å forbedre det terapeutiske 
utfallet av flere legemidler, men til nå er det ingen tilgjengelige nano-formuleringer med DOC. 
Det er derfor interessant å undersøke om en liposomal formulering med DOC kan løse 
legemidlet og forbedre det terapeutiske utfallet. 
FORMÅL: Målet med denne oppgaven var å etablere en metode for tillaging og karakterisering 
av DOC-liposomer i liten skala, for videre å undersøke effekten av ulike lipidkomposisjoner 
for inkorporering av legemiddel.  
METODE: DOC-liposomer ble fremstilt av ulike lipidkomposisjoner ved bruk av «thin-film 
hydration» metode og størrelsesredusert ved hjelp av sonikering. Sentrifugering ble brukt som 
metode for å fjerne fritt legemiddel fra den liposomale formuleringen. Effekten av ulike 
lipidkomposisjoner på inkorporering av legemiddel ble undersøkt med karakterisering av de 
ulike lipsomale formuleringene. 
RESULTATER: De 14 ulike liposomale formuleringene med ulik lipidkomposisjon og 
legemiddel:lipid ratio på 10:1 (vekt/vekt) viste en inkorporering mellom 18 og 115 %. Tre av 
de liposomale formuleringene viste inkorporering av DOC nær 100 % og ble undersøkt videre 
ved å øke legemiddel:lipid ratio til 2:10 (vekt/vekt) for å se om mer DOC kunne inkorporeres i 
liposomene. Økt legemiddel:lipid ratio reduserte inkorporering av DOC i liposomene for alle 
tre formuleringene, men soya-fosfatidylkolin (SPC) og positive ladet 1,2-Dioleoyl-3-
trimethylammonium-propane (DOTAP) (8:2 vekt/vekt) formuleringen hadde den høyeste 
DOC-konsentrasjonen. Vi undersøkte derfor effekten av å variere konsentrasjonen av DOTAP 
i forhold til SPC. Resultatene viste at en høyere konsentrasjon av DOTAP ga et høyere utbytte 
av DOC. 
KONKLUSJON: Vi lyktes med å etablere en småskala metode for å screene ulike liposomale 
formuleringer for deres evne til å ta opp DOC i liposommembranen. I screening studien fant vi 
at liposomale formuleringer som inneholdt det kationiske lipidet DOTAP viste bedre 
inkorporering av de ulike liposomkombinasjonene som ble undersøkt. En økende mengde 
DOTAP i SPC:DOTAP liposomer viste en økende inkorporering av DOC. 
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INTRODUCTION: Docetaxel (DOC) is a potent anticancer drug but has several limitations 
such as poor solubility. The currently commercially available formulation of DOC is limited 
by reported serious side effects which either is attributed to the drug itself or the solvent used. 
Nanomedicine has been used for improving the therapeutic outcome of several drugs, but so far 
there are none available with DOC. It would be interesting to apply a liposomal formulation for 
delivery of DOC in order to solubilize the drug and improve the therapeutic outcome. 
OBJECTIVES: The aim with this master project was to establish a small-scale screening 
method for making and characterizing DOC liposomes and further investigate the effect of lipid 
composition on drug entrapment to find a suitable liposomal formulation of DOC. 
METHODS: DOC liposomes were made of different lipid compositions by a thin-film 
hydration method and size reduced by probe sonication. Centrifugation was used to remove 
free DOC from the liposomal formulation. The effect on varying lipid compositions on drug 
entrapment were tested with characterization of the liposomal formulations. 
RESULTS: The 14 different liposomal formulations with varying lipid compositions and a 
drug:lipid ratio of 1:10 (w/w) showed an entrapment efficiency between 18 and 115 %. Three 
of the liposomal formulations showed entrapment efficiency near 100 % and were further 
investigated by increasing the drug:lipid ratio to 2:10 (w/w) to see if more DOC could be 
entrapped in the liposomes. The DOC recovery were low for all three formulations, although 
the soy phosphatidylcholine (SPC):DOTAP liposomes showed a higher recovery compared to 
the other two. The SPC:DOTAP were brought further to investigate the effect of varying the 
concentration of DOTAP, and the results showed that a higher DOTAP concentration gave a 
higher recovery of DOC. 
CONCLUSION: A small scale screening method for investigating the effect of different 
liposomal formulations on the archived DOC entrapment was established successfully. The 
liposomes with cationic lipid, DOTAP, showed best entrapment efficiency of the different 
liposomal combinations screened. Increasing amount of DOTAP within SPC:DOTAP 
liposomes showed a greater incorporation of DOC. 
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1 General introduction 
Cancer causes millions of deaths each year and is the second leading cause of death globally 
(WHO, 2018). The first line treatment for most cancers today are surgery, radiation and 
chemotherapy (Kumari et al., 2016). Although docetaxel (DOC) is one of the most important 
cytotoxic agents in clinic today, it has several limitations such as poor solubility, nonselective 
distribution and fast elimination. In the currently commercially available formulation of DOC, 
it has been reported serious side effects such a neutropenia, musculoskeletal toxicity, peripheral 
neuropathy and hypersensitivity, which either can be attributed to the drug itself or to the 
solvent used (polysorbate 80) (Tan et al., 2012).  
Nanomedicine is a technology in which special drug systems, drug delivery systems, uses nano 
sized particles, including liposomes for medical applications (Nehoff et al., 2014). In general, 
employment of drug delivery systems with a carrier and an entrapped drug can improve the 
pharmacological properties of the drug compared with the conventional “free drug” (Allen and 
Cullis, 2004). 
Liposomes is an attractive drug carrier of several reasons. First, both hydrophilic and lipophilic 
drugs can be encapsulated or entrapped in liposomes (Tan et al., 2012). Second, the membrane 
composition of liposomes can be altered and composed of a variety of lipids and lipid 
combinations which in turn can change the organization of the membrane, charge and stability 
(Brandl, 2001). Third, size can be altered which is favourable in terms of longer half-life and 
altered pharmacokinetics (Fanciullino and Ciccolini, 2009; Bozzuto and Molinari, 2015). 
Fourth, liposomes are in general non-toxic, biocompatible and biodegradable (Akbarzadeh et 
al., 2013). Fifth, liposomal formulations are often applied to solubilize the drug which is 
beneficial with poorly soluble drugs (Laouini et al., 2012). Finally, liposomes could be 
modified with targeting moieties to achieve active targeting, or modified to achieve a triggered 
release mechanism, or altered with surface modifications to give long circulating liposomes. 
In the last decades, extensive research has been done to incorporate drugs into liposomes to 
improve therapeutic outcome, and currently several formulations are commercially available 




It is desirable to overcome the limitations and side effects alongside with improving the 
anticancer effects of DOC compared to the currently commercially available DOC formulation. 
Hence there is comprehensive focus on studies on applying a nanocarrier with DOC entrapped 
to overcome these problems. As far as we are concerned, there is no commercially available 
nanocarrier with DOC to this date (Louage et al., 2017). Hence, it is desirable to develop a 
liposomal formulation which shows good tolerability, minimal side effects and a good 
therapeutic effect. 
By applying a liposomal formulation for DOC entrapment to solubilize the highly lipophilic 
drug, one could avoid the use of Polysorbate 80. The partition coefficient and polarity of a drug 
determines where the drug will be located in the liposomal membrane, and further the 
entrapment efficiency of the drug (Bozzuto and Molinari, 2015). Lipophilic drugs, like DOC, 
can be entrapped in the lipid bilayers of the liposome (Tan et al., 2012) and because of their 
lipophilic nature they reside in the acyl chains of the liposome. The entrapment efficiency of 
drugs is dependent on the acyl chain properties, like length of acyl chain and packing density, 
in addition to changes in the drug:lipid ratio (Bozzuto and Molinari, 2015). 
We aimed at development of a liposomal formulation with DOC incorporated in the lipid 
bilayer. To find a suitable formulation, we explored the effect of lipid composition in liposomes 






2.1 Cancer-targeted drug delivery 
According to the World Health Organisation (WHO), cancer is the second leading cause of 
death globally, responsible for 8.8 million deaths in 2015. Cancer is a collective term applied 
for a numerous of diseases which can affect any part of the body, and the most common causes 
of cancer deaths are lung cancer, liver cancer, colorectal cancer, stomach cancer and breast 
cancer. Cancer is caused by transformation of normal cells into tumour cells in a complex 
process which progresses from pre-cancerous lesion to malignant tumour (WHO, 2018). 
Today the first line treatment for most cancers are surgery, chemotherapy and radiation. 
Chemotherapy is a highly non-specific strategy in targeting drugs to cancer tissues which leads 
to undesirable side effects to healthy tissues (Kumari et al., 2016). As a consequence, healthy 
proliferative cells in bone marrow, hair follicles and the gastrointestinal tract gets killed and 
thereby leading to common side effects like compromised immune defence because of 
decreased production of leukocytes, platelets and red blood cells, hair loss and inflammation 
and ulceration of mucus membranes in the gastrointestinal tract (Dawidczyk et al., 2014). Thus, 
conventional chemotherapy drugs suffers from several limitations, like severe toxicity to 
normal cells, non-specific biodistribution, inadequate drug concentrations at cancer cells, 
development of multiple drug resistance and poor aqueous solubility (Kumari et al., 2016). 
Nanomedicine and application of nanoparticles (NPs) as drug delivery systems for treatment of 
cancer have received extensive attention in recent years (Kumari et al., 2016). Nanomedicine 
is a branch under nanotechnology which are focused on development of pharmaceuticals 
(Etheridge et al., 2013), where use of special drug delivery systems are used for medical 
applications like treatment of cancer, medical imaging and diagnostics (Nehoff et al., 2014). 
The European Science Foundation (ESF) defined nanomedicine in 2004 as: “The field of 
Nanomedicine is the science and technology of diagnosing, treating and preventing disease and 
traumatic injury, of relieving pain and of preserving and improving human health, using molecular tools 
and molecular knowledge of the human body…. The aim of “Nanomedicine” may be broadly defined 




biological systems, working from the molecular level using engineered devices and nanostructures, 
ultimately to achieve medical benefit” (European Science Foundation, 2004). 
A drug delivery system consists of a carrier and a therapeutic drug (Jain, 2008). The drug 
delivery system-carrier can be a NP generally composed of lipids or polymers which are 
designed to improve the therapeutic and pharmacological properties of the therapeutic drug. In 
general, employment of drug delivery systems with a carrier and an entrapped drug can improve 
the pharmacological properties of the drug compared with the conventional “free drug” (Allen 
and Cullis, 2004). The drug delivery process includes administration of the drug delivery 
system, release of the therapeutic drug by the carrier, transport of the therapeutic drug across 
the biological membranes to the desired site of action (Jain, 2008).There are several types of 
nanoparticles used for drug delivery carriers, such as liposomes, micelles, polymeric 
nanoparticles, polymeric micelles, dendrimers, carbon nanotubes, nano-shells, viral 
nanoparticles and inorganic (metal) nanoparticles (Cho et al., 2008; Kumari et al., 2016). 
NPs offers several advantages in treatment of cancerous diseases which make them attractive 
compared to conventional chemotherapy. A major advantage with NPs is that they can improve 
solubility by solubilize poorly soluble, lipophilic drugs in hydrophobic compartments and 
therefore improve the pharmacokinetics of the drug compared to conventional medicine 
(Kumari et al., 2016). 
Another important property of NPs is the size in nano-range that could alter the 
pharmacokinetics of the drug and favour nanomedicine over conventional medicine (Nehoff et 
al., 2014). Conventional drugs may have a widespread distribution in the body which may affect 
normal, non-target tissues. Employment of a drug entrapped in a NP will on a general basis 
affect the clearance of the drug in direction downwards, so the half-life increases, the 
distribution volume decreases and the area under the time versus concentration curve increases 
(Allen and Cullis, 2004; Nehoff et al., 2014). The lower distribution volume will reduce the 
impact and potential side effects in normal tissues (Allen and Cullis, 2004). 
NP employed for cancer treatment can enhance safety, bioavailability and therapeutic efficacy 
compared to conventional therapy. NPs can exploit an inherent passive targeting phenomenon, 





Many solid tumours have a unique pathophysiologic characteristic that distinguish them from 
healthy tissue, which anticancer drugs can exploit (Natfji et al., 2017). Many cancer cells grow 
fast and therefore demands energy in form of nutrients and oxygen, which leads to development 
of new blood vessels, a process called neovascularization, or recruitment of nearby existing 
blood vessels to supply the tumour cells. This results with highly disorganized angiogenic blood 
vessels and dilated tumours with enlarged gaps between the endothelial cells, which enables 
macromolecules, including NPs, to permeate and accumulate in tumour tissues (Cho et al., 
2008; Natfji et al., 2017).  
In addition, tumours show lack of- or compromised lymphatic drainage, hence NP gets retained 
present in the interstitial fluid of tumours for a longer time compared to normal tissues which 
have functional lymphatics (Peer et al., 2007). The result of the enhanced permeability of the 
tumours vascularity together with compromised lymphatic drainage leads to passive and to a 
certain extent, selective accumulation of extravasated macromolecules inside tumour cells, 
which in turn reduces the clearance from the tumour tissue (Natfji et al., 2017). This is called 
the enhanced permeability and retention (EPR) effect, illustrated in Figure 1 (Kumari et al., 
2016). 
 
Figure 1: A schematic illustration of the Enhanced Permeability and Retention effect is imagined to take place in 




NPs tends to exploit the enhanced permeability and retention (EPR) effect, especially to 
tumours and inflamed tissues. Because of their small size, NPs can extravasate through cellular 
barriers. 
There are several factors that determine the efficacy of anticancer drugs. First, the ability to 
penetrate a variety of barriers and reach the tumour without losing activity or amount drug when 
traveling through the blood circulation is crucial. Second, the drug should have the ability and 
selectivity to avoid killing normal cells and tissue, but only affect tumour cells in a controlled 
manner (Cho et al., 2008). 
It is crucial for the drug to stay in the blood circulation for sufficient enough time to effectively 
reach the tumour. The chance of being caught by the mononuclear phagocyte system (MPS) is 
high if the NPs have unmodified surface characteristics. The fate of injected NPs can, to a 
certain extent, be controlled by modifying the size of the NPs and modifying the surface 
characteristics like making the surface of a NP hydrophilic. The surface can be modified to be 
more hydrophilic by coating the surface with polyethylene glycol (PEG) which is a hydrophilic 
polymer, a process known as PEGylation. PEGylation will protect NPs from opsonization by 
macrophages by repelling them (Cho et al., 2008). 
 
2.1.1 Docetaxel 
N-debenzoyl-N-tert-(butoxycarbonyl)-10-deaxetyltaxol, or docetaxel (DOC) is a semisynthetic 
Taxol/paclitaxel analogue (Guéritte-Voegelein et al., 1991) which belongs to the taxane family, 
a class of anticancer drugs (Immordino et al., 2003). DOC is prepared by semi synthesis from 
10-deacetylbaccatin-III, which are an inactive precursor that are isolated from needles of the 
European yew tree, Taxus baccata (Zhang and Zhang, 2013). DOC is used for treatment of 
breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and 
neck cancer (Louage et al., 2017). 
Both DOC and paclitaxel are poorly soluble drugs. The chemical structure of DOC in Figure 2 
shows a complex taxane ring that is linked to an ester at the C-13 position. The hydrophobic 
domains of the fused ring system and side chain of DOC contributes to poor aqueous solubility 




because of the chemical structure, specifically a tertbutyl carbamate ester in the 
phenylpropionate side chain in addition to a hydroxyl group on C-10 (Tan et al., 2012).  
 
Figure 2: Chemical structure of docetaxel. 
 
DOC lipophilic nature causes a limited solubility in aqueous medium (Tan et al., 2012). Since 
DOC is practically insoluble (4.03 µg/mL) in water, the only currently available formulation is 
parenterally administrated (Yin et al., 2009), formulated in a 50:50 (v/v) ethanol:polysorbate 
80 formulation, commercially branded Taxotere® (Pereira et al., 2016; Louage et al., 2017). 
Polysorbate 80 is a surfactant which can cause serious hypersensitivity reactions and induce 
fluid retention and therefore have to be pre-treated with antihistamines and/or corticosteroids 
to avoid severe or fatal allergic reactions, and diuretics if swelling due to fluid retention (Louage 
et al., 2017). The currently commercially available formulation of DOC have reported to cause 
serious side effects like neutropenia, musculoskeletal toxicity, peripheral neuropathy and 
hypersensitivity reactions which either is attributed to polysorbate 80 or to DOC itself (Tan et 
al., 2012).  
In order to solubilize DOC, one could employ a liposomal formulation. There have been 
developed alternative dosage forms such as liposomes (Deeken et al., 2013; Mahalingam et al., 
2014), micelles, polymeric nanoparticles and cyclodextrin complexes in order to eliminate 




adverse reactions (Manjappa et al., 2013; Naik et al., 2010). However, none of these 
formulations are commercially available but under clinical investigations for now.  
Two of the formulations under clinical trials are liposomal formulations; ATI-1123 and LE-DT 
(Louage et al., 2017). The ATI-1123 liposomal formulation of DOC was composed of 
phospholipids (PLs), cholesterol (Chol), human serum albumin and sucrose (Mahalingam et 
al., 2014). The LE-DT liposomal formulation of DOC was composed of negatively charged 
synthetic PLs and Chol (Deeken et al., 2013). Both ATI-1123 and LE-DT is currently under 
phase I and II clinical trials, respectively, and subject to a patent situation (Louage et al., 2017) 
and therefore there is little information about which PLs that were used. The results from the 
clinical trials of ATI-1123 and LE-DT have reported good tolerability, predictable and 
manageable toxicity and promising antitumor effect (Mahalingam et al., 2014; Deeken et al., 
2013). 
 
2.1.1.1 Mechanism of action 
DOC is an antineoplastic agent in which the antitumor mechanism of action is hyper-
stabilization of microtubules. By binding to the β-subunit protein of tubulin on the 
microtubules, DOC promotes assembly of tubulin into stable microtubules and simultaneously 
inhibition of microtubule depolymerization. The normal dynamic equilibrium between 
polymerization and depolymerization within the microtubule system is disrupted because of the 
formation of stable microtubule bundles and hence lead to cell cycle arrest at the G2/M phase 
and cell death (Zhang and Zhang, 2013; Tan et al., 2012). Cell death is a result of a significant 
reduction in free tubulin, inhibition of mitotic cell division and prevention of cancer cell 
proliferation (Xie et al., 2016). To achieve therapeutic efficacy, DOC is dependent on being 







2.2.1 Characteristics of liposomes 
Liposomes are lipid based nanoparticles with a spherical shape in where an aqueous core lies 
between a lipid bilayer (Kim, 2016). The size of liposomes can range from a few nanometres 
to several micrometres. Liposomes seem to have ideal properties as a drug carrier system 
because of their ability to entrap different substances together with their morphology which is 
similar to cellular membranes (Bozzuto and Molinari, 2015). Because of this, a lot of interest 
and research have been carried out with this nanocarrier system since the discovery of 
liposomes in the 1960s by Alec D. Bangham (Bozzuto and Molinari, 2015; Bangham et al., 
1965).  
The liposomes are primarily composed of phospholipids (PL) that are either originated from 
plants or egg. In addition, liposomes can include Chol, sphingolipids, glycerolipids, long-chain 
fatty acids, membrane proteins and nontoxic surfactants (Kaur et al., 2014).  
The liposomes are arranged in bilayers, as shown in Figure 3, where the lipids arrange 
themselves so that hydrophilic head groups of the PLs points toward the aqueous phases, that 
is both outside and inside the vesicle, making the core hydrophilic, while the hydrophobic 
chains of the PLs is forming the inner core of the lipid bilayers (Kumari et al., 2016). Liposomes 
can have one or more lipid bilayers, named unilamellar (ULVs) and multilamellar vesicles 
(MLVs), respectively (Kraft et al., 2014). Poorly soluble, lipophilic drugs or compounds can 
be entrapped in the lipid bilayers as shown in Figure 3, while hydrophilic, water-soluble drugs 





Figure 3: Cross section of a liposome with a phospholipid bilayer. Lipophilic drugs are entrapped in the 
phospholipid bilayer (Sætern, 2004) (with permission). 
 
The partition coefficient and polarity of a drug determines where the drug will be located in the 
liposomal membrane, and further the entrapment efficiency of the drug (Bozzuto and Molinari, 
2015). Because of DOCs high lipophilicity, it is conceivable that the drug will reside in the 
fatty acyl chains of the liposome. The entrapment efficiency of DOC is dependent on the acyl 
chain properties, like length of acyl chain and packing density, in addition to changes in the 
drug:lipid ratio (Bozzuto and Molinari, 2015). 
The liposomal properties vary substantially with composition of lipids, preparation methods, 





2.2.2 Membrane components in liposomes 
The membrane composition of the liposomal membrane might be varied by selecting different 
lipids and lipid combinations, that will ultimately change liposomal features like phase 
transition temperature (Tm), stability and charge. Which lipid(s) that are chosen will affect the 
stability of the liposomes both in vitro and in vivo and the stability of the drug. Choice of lipid 
affects the organisation and properties of the PL membrane like elasticity, permeability and 
binding of a drug (Brandl, 2001). Several studies have showed that composition of the lipid 
bilayer affects the entrapment of DOC in liposomes (Pereira et al., 2016; Naik et al., 2010; 
Manjappa et al., 2013; Immordino et al., 2003). 
The lipids used to form the bilayer will determine the rigidness or “fluidity” of the membrane 
and the charge of the bilayer (Akbarzadeh et al., 2013). A key parameter for liposomal systems 
is the gel to liquid crystalline Tm in which the structure of the bilayer loses the ordered packing 
because the hydrocarbon chains melts. The longer the length of the hydrocarbon chain is, the 
higher the Tm is (Taylor et al., 2005), due to van der Walls interactions which is stronger and 
thus require more energy to disrupt the ordered packing (Bozzuto and Molinari, 2015). In 
addition, strong head group interactions and increasing saturation of the fatty acid will increase 
the Tm (Taylor et al., 2005). If saturated PLs with long acyl chains is chosen as components, it 
will form a rigid and impermeable bilayer, whereas unsaturated PLs from natural sources gives 
a less stable bilayer that is more permeable (Akbarzadeh et al., 2013). 
 
2.2.2.1 Phospholipids 
Phospholipids (PLs) or glycerophospholipids are a subclass of lipids which are a key 
component of all cell membranes (Singh et al., 2017). PLs contain phosphorus, an polar part 
and a non-polar part (Li et al., 2015). They are amphiphilic molecules which means that they 
are composed of a hydrophilic head group and hydrophobic acyl chain-tails (Bozzuto and 
Molinari, 2015), that are linked to alcohol (Figure 4). The polar head groups will be oriented 





Figure 4: Illustration of the general structure of phospholipids and how they arrange themselves in bilayers. 
 
PLs might differ in their composition by containing different alcohols, head group, acyl chains, 
or also by source of PL. PLs that vary in the alcohols can be divided into glycerophospholipids 
and sphingomyelins. PLs that vary in the structure of the head group gives rise to different PLs 
like phosphatidylcholine (PC), phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) 





Figure 5: Illustration of commonly used phospholipids for liposomal formulations. The R1 and R2 groups 
represents the fatty acyl tail groups (Inspired by (Kraft et al., 2014)). 
 
The fatty acyl chains (tail group presented in Figure 5 by R1 and R2) of the PL are typically 14-
18 carbons in length and have varying saturation (Kraft et al., 2014). Dipalmitoyl with 16 
carbons and distearoyl with 18 carbons, both saturated fatty acid chains, are popular choices 
for lipid bilayers. Dioleoyl is an unsaturated fatty acid chain with 18 carbons which also are 
commonly used (Alipour et al., 2017). 
Table 1 comprises examples of different lipids with different head groups and fatty acyl chains. 
These lipids are used in this master project. The head groups is either PC, also referred to as 
lecithin which has a neutral charge and are a major building block in membranes, PE which 
carry a neutral charge at physiologic pH 7.4 and PG which carry a negative net charge at 





Table 1: Examples of different lipids with different head groups: PC, PE and PG. The fatty acyl groups vary in 



















































The source of the PLs can be categorized accordingly (Samad et al., 2007): 
• Natural source. 
• Modified from a natural source. 
• Semisynthetic. 
• Synthetic. 
PLs have excellent biocompatibility which makes them attractive as pharmaceutical excipients 
and applications in drug delivery systems. When PLs is hydrated in aqueous medium, they will 
form in different assemblies like liposomes or micelles (Li et al., 2015). In the case of 
liposomes, PLs and eventually other adjacent lipid molecules interact and align to form a 
contiguous bilayers sheet, which will form enclosed vesicles in solution (Kraft et al., 2014). 
 
2.2.2.2 DOTAP 
1,2.Dioleoyl-3-trimethylammonium-propane (DOTAP) is a cationic lipid which consists of two 
unsaturated fatty acids, oleoyl chains which is bound by an ester bond to a glycerol backbone. 
The cationic head group is a quaternary ammonium salt (Zhi et al., 2018). The chemical 





Figure 6: The chemical structure of 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP). 
 
2.2.2.3 Ceramides (Sphingolipids) 
Ceramides is a class of sphingolipids which are composed of two distinct functional 
components, the sphingosine structure and the esterified fatty acyl chain (Stillwell, 2016a). The 
acyl chains vary in length, where endogenous ceramide species commonly have 16-24 carbon 
atoms. In this master project we used ceramide C6 shown in Figure 7 and ceramide C12 shown 
in Figure 8.  
 
Figure 7: The chemical structure of Ceramide C6 
 
Figure 8: The chemical structure of Ceramide C12 
 
2.2.2.4 Cholesterol (sterols) 
Cholesterol (Chol) is a hydrophobic molecule, shown in Figure 9, with the exception of a polar 
-OH group which is anchored to the aqueous interface (Stillwell, 2016b). Chol can increase the 
packing of PL molecules and decrease the mobility of hydrocarbon chains, and therefore reduce 




of drug (Brandl, 2001; Dawidczyk et al., 2014). Chol also change the fluidity of the intravesical 
interactions between the head groups and hydrocarbon chains which make the lipid bilayer 
more rigid (Briuglia et al., 2015) and hence decrease the Tm (Taylor et al., 2005). Studies have 
showed that inclusion of a small amount of Chol does not have a negative effect on entrapment 
of drugs, however, increasing amount of Chol in a liposomal formulation had a negatively effect 
on drug loading (Mohammed et al., 2004; Immordino et al., 2003; Chen et al., 2017).  
 
Figure 9: The chemical structure of cholesterol. 
 
2.2.2.5 PEGylation 
Conventional liposomal formulations have been hampered by short circulation time in the 
bloodstream because of uptake by the mononuclear phagocyte system (MPS) (Kim, 2016). 
Polyethylene glycol (PEG) is a polymer which often is attached to the surface of nanoparticles 
to make the detection by the MPS more difficult. This process is called PEGylation (Bulbake 
et al., 2017; Kumari et al., 2016) and have been shown to improve the stability and circulation 
time of liposomes after intravenous administration (Bozzuto and Molinari, 2015).  
PEGylated liposomes are also referred to as Stealth™ liposomes or long circulating liposomes. 
Among various surface modifying molecules, PEG is popular because of its properties 
including conformationally flexibility, high mobility and hydrophilicity which contribute to 
decreased interactions with various plasma proteins and uptake by the MPS (Kim, 2016). 
DSPE-PEG2000, shown in Figure 10, is a PEGylated PL which is applied in different 
preparations, including Doxil® and used in this master project. The PEG layer is grafted onto 





Figure 10: The chemical structure of 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) with 
polyethylene glycol (PEG)-2000. 
 
2.2.3 Methods for preparation of liposomes 
2.2.3.1 Film-hydration method 
There are several methods for preparation of liposomes, and one of the most common used is 
the thin-film hydration method, also called Bangham-method (Bozzuto and Molinari, 2015; 
Bangham et al., 1965), which is the method applied in this project. Other methods for 
preparation of liposomes include reverse-phase evaporation, freeze-drying and ethanol 
injection (Laouini et al., 2012; Kim, 2016). In the thin-film hydration method the lipids and 
drug are dissolved in an organic solvent, then the solvent is evaporated by rotary evaporation 
to get a lipid film. The lipid film is rehydrated with an aqueous solvent (Bulbake et al., 2017). 
 
2.2.3.2 Sonication 
There are several ways to control and reduce the size of liposomes such as extrusion, 
homogenization and/or freeze-thawing, and sonication (Bulbake et al., 2017). Sonication is the 
method applied in this project. Sonication is an extensively used method for reduction of size, 
and there are two different techniques to sonicate: probe sonication and bath sonication 
(Akbarzadeh et al., 2013). Probe sonication is the technique applied in this project and involves 
a probe, the tip of the sonicator, that is directly applied into a liposomal dispersion. The probe 
transmits energy in form of ultrasonic irradiation to the lipid dispersion and thereby reduces the 
size of the vesicles (Bozzuto and Molinari, 2015). Under the ongoing process the probe is 
heated, and this heat is also transferred to the liposomal dispersion. To avoid extensive heating 






2.2.4 Size and surface charge of liposomes 
The ideal size of a liposome depends on several biological conditions. The size should be small 
enough to avoid being captured by macrophages in the MPS and to exploit the gaps between 
the endothelial cells of the tumour with leaky vasculature ranging from 100-500 nm to enter 
the interstitial space (Bozzuto and Molinari, 2015) and at the same time be big enough to 
prevent being leaked into the capillaries from the tumour site (Cho et al., 2008). 
The size of conventional liposomes determines the fraction cleared by the MPS and it have 
been shown that small liposomes (e.g. size below 100 nm) are opsonized less rapidly and to a 
lower extent compared bigger liposomes (e.g. bigger than 100 nm) (Fanciullino and Ciccolini, 
2009). On the other hand, liposomes with a diameter < 10 nm rapidly cleared by the kidney 
(Kumari et al., 2016). 
Studies indicate that particles should have a diameter below 200 nm to effectively get 
extravasated into tumours (Peer et al., 2007), and that a reduction on size of liposomes has been 
correlated with increased accumulation in tumours. It has been displayed that small liposomes 
shows a longer half-life compared to larger liposomes (Fanciullino and Ciccolini, 2009). 
Therefore, the ideal size of liposomes for reaching the tumours should be 50-100 nm in diameter 
(Bozzuto and Molinari, 2015; Kumari et al., 2016). 
The charge of liposomes depends on the lipid composition and head group of lipids, which is 
typically expressed as surface charge or zeta potential, ζ (Kraft et al., 2014). The zeta potential 
is one of the characteristics measured of liposomes and give an index of the magnitude of the 
repulsive interaction between colloidal particles (González-Paredes et al., 2010). Liposomes 
may carry a negative, neutral or positive net charge (Kraft et al., 2014). The surface charge may 
influence kinetics, stability, interaction with and uptake of liposomes by target cells and extent 
of biodistribution (Lian and Ho, 2001). Increasing zeta potential shows a tendency that charged 
particles will repel one another and hence not aggregate (Alipour et al., 2017). 
Cationic lipids, lipids with a positive charge, have been shown to be rapidly eliminated by the 
MPS (Allen and Cullis, 2013; Kraft et al., 2014). Also, negative surface charge is recognized 
by receptors on different cells, like macrophages, and when entering the circulation, the 




charge show enhanced cellular uptake through endocytosis compared to natural counterparts 
(Kraft et al., 2014). 
 
2.2.4.1 Classification of liposomes according to structure and size 
Based on structure classification, the liposomes are classified with respect to type of vesicle 
together with size and number of lipid bilayers that enclose the aqueous phase (Samad et al., 
2007; Maheswaran et al., 2013): 
• Unilammelar vesicles (UVs): all diameter size range, with one lipid bilayer. 
• Small unilamellar vesicles (SUVs): 20-100 nm in diameter, with one lipid bilayer. 
• Medium unilamellar vesicles (MUVs): >100 nm in diameter, with one lipid bilayer. 
• Large unilamellar vesicles (LUVs): >100 nm in diameter, with one lipid bilayer. 
• Giant unilammelar vesicles (GUVs): >1 µm in diameter with one lipid bilayer. 
• Oligolamellar vesicles (OLVs): 0.1-1 µm in diameter with approximately 5 lipid 
bilayers. 
• Multilamellar vesicles (MLVs): > 0.5 µm in diameter with 5-25 lipid bilayers. 
• Multi vesicular vesicles (MVs): >1µm in diameter where the lipid bilayers have multi 
compartmental structure (Samad et al., 2007; Maheswaran et al., 2013). 
Lamellarity is a feature of the membrane structure which indicate number of bilayers the 
membrane it is composed of. If the membrane has a single bilayer, it is called unilamellar, but 
if the membrane has many bilayers it is called multilamellar, as shown in Figure 11 (van Swaay 
and deMello, 2013). Often, liposomes could be in between the categories in the above 
mentioned classification, and without any characterization with small angle X-ray scattering 
evaluation or electron microscopy it is difficult to know how many lamella there is within the 





Figure 11: The size and lamellar structure of different classes of liposomes (Inspired by (van Swaay and deMello, 
2013). 
 
2.2.5 Liposomes used as drug delivery systems 
The first drug delivery system which have made success translating into clinical applications 
are liposomes. In 1995 Doxil®, a liposomal formulation of doxorubicin, entered the U.S. 
marked. Doxil® was approved for treatment of ovarian cancer and AIDS-related Kaposi´s 
sarcoma. Most of the liposomal formulations that have been developed are used for cancer 
treatment, but there are also liposomes used for treatment of fungal- or virus infections or pain 
management (Bulbake et al., 2017). To this day there is approximately 15 liposomal 
formulations on the marked (Bulbake et al., 2017; Kim, 2016). 
The research conducted on liposomes has progressed from conventional liposomes, also 
referred to as “first-generation liposomes” to long circulating liposomes in which surface 
modifications, lipid composition and size of the vesicle is modified (Immordino et al., 2006). 
Liposomes can also be modified with targeting moieties such as monoclonal antibodies, 
peptides or receptor ligands to achieve active targeting, or liposomal formulations can be 
modified to achieve triggered release, achieved by pH- or temperature sensitivity (Allen and 
Cullis, 2013). 






Table 2: Advantages and disadvantages of liposomes used in drug delivery systems. 
Advantages  Disadvantages 
Liposomes are in general non-toxic, flexible, 
biocompatible, completely biodegradable 
and non-immunogenic both for systemic and 
non-systemic administrations (Akbarzadeh 
et al., 2013). 
Production cost is high (Akbarzadeh et al., 
2013) and mass production is challenging 
(Kim, 2016). 
Entrapment of both hydrophilic and 
lipophilic drugs is feasible (Kim, 2016). 
A short half-life after i.v. administration due 
to rapid clearance from the bloodstream by 
the mononuclear phagocytic system (MPS) 
(Naik et al., 2010; Immordino et al., 2006). 
Changed biodistribution of the drug might 
lead to reduced exposure of toxic drugs to 
sensitive or normal tissues (Akbarzadeh et 
al., 2013). 
Can increase drug stability via 
incorporation, by protecting the drug by 
entrapment and thereby isolating the drug 
from the surrounding environment 
(Akbarzadeh et al., 2013; Peer et al., 2007). 
Stability issues might lead to a burst drug 
release (Peer et al., 2007). PLs are prone to 
chemical degradation reactions, like 
oxidation and hydrolysis (Akbarzadeh et al., 
2013). 
Flexible in formulation: size, charge and 
surface functionality can be modified either 
through addition of agents to the lipid 
membrane or by alteration of the surface 
(Peer et al., 2007). 
Active targeting is possible when coupled 







3 Aim of the study 
The aim of this master project was to establish a suitable small-scale screening method for 
making DOC-liposomes, and for separating the unentrapped DOC from the DOC-liposomes 
for further determination of the drug entrapment efficiency. This methodology was applied to 
examine different PL compositions aiming to decide which factors are affecting how well DOC 
is taken up and becomes a part of the liposomal membrane. 
Specific aims: 
• Pilot project: validate the method for making and testing the different DOC liposomal 
formulations. 
• Screening study: screening of 14 different lipid combinations to investigate how the 
different liposomal formulations affect the DOC entrapment efficiency. 
• Further, to challenge the liposomal formulations showing best entrapment of DOC in 
the Screening study, by increasing the DOC concentration to examine if increasing the 
DOC concentration also would give an increase in DOC entrapment.  
• Finally, varying the concentration of positively charged lipids, DOTAP, in the 










4 Materials, instruments and experimental section 
4.1 Materials 
4.1.1 Chemicals 
Table 3: Specifications of the chemicals used in this study.  




≥ 99.8 % 
Lot: 
#SZBD1760V 















Sigma Aldrich Chemie GmbH, 
USA 
Chloroform 99.0-99.4 (GC) Lot: 
#STBF8245V 
Sigma Aldrich Chemie GmbH, 
Steinheim, USA 
Distilled water   Distillation unit Distinction 
D4000, Bibby Sterlin LDT, 
Staffordshire, UK 




96 % (v/v) Lot: 
17E224011 






Sigma Aldrich Chemie, GmbH, 
USA. 










ACS reagent Lot: 
SZBE1360V 
Sigma Aldrich, Austria 
Hydrogen 
peroxide, H2O2 
30 % H2O2  









≥ 99.9 % 
Lot: 
#SZBC272MV 
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
MilliQ water   MilliQ gradient, Millipore 
Water purification system with 
Millipak® M 0.22µm filter 
(LOT NO C5MA58154), 

























Table 4: Specifications of the lipids used in the liposomal formulations in this study. 






















Sigma Aldrich Co, 






























Sigma Aldrich Co, 
St. Louis, USA. 
DOPE 1,2-Dioleoyl-sn-glycero-
3-phosphoethanolamine 
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4.1.3.1 Mobile phases for HPLC-analysis: 
Mobile Phase A: 
I. MilliQ Water  1998.0 mL 
II. Formic acid  2.0  mL 
Mobile Phase B: 
I. Acetonitrile  1998.0 mL 
II. Formic acid  2.0 mL 
 
4.1.3.2 Solutions prepared for PC-assay: 
Fiske SubbaRow reducer: 
3.0 g Fiske SubbaRow reducer 
18.9 mL distilled water. 
Ammonium Molybdate 0.22 % (v/v): 
0.88 g ammonium molybdate powder 
Ad 400 mL distilled water 
H2SO4 10 N: 
10.88 mL H2SO4 
29.12 mL distilled water 
HCl 0.5M: 
0.411 mL HCl 




4.2 Equipment and instruments 
Balances: Sartorius BP211D, Sartorius LP4200S, Sartorius CP225D, Sartorius AG, Göttingen, 
Germany. 
Benchtop centrifuge: Biofuge Stratos with Heraeus rotor #3048 and #8172, Heraeus 
Instruments, UK. 
Drying oven: Termaks TS8056 Bench Top Drying Oven, Termaks a/s, Bergen, Norway 
HPLC: Waters e2795 separations module connected to a Waters 2489 UV/Visible detector and 
a C-18 column: XSELECT CSH XP (2.5 µm 3.0x75 mm). (Waters, Dublin, Ireland). 
LAF-bench: Holten LaminAir, Maxi Safe 2000, Allerød, Denmark. 
Particle Size Analysis and Zeta Potential Measurement: Zetasizer Nanoseries ZS, Malvern 
Instruments Limited, Worcestershire, UK. 
Rotary evaporator: Büchi Waterbath B480, Büchi Vac V-500, Büchi vacuum controller B-721, 
Büchi rotavapor R-124, Büchi labortechnik, Flawil, Schwitzerland. 
Sonicator: Sonics Vibra Cell Probe sonicator, autotune series high intensity ultrasonic processor 
VC 754 750 watt Ultrasonic processor, CVR 234 Converter, Probe 19 mm, Sonics and 
Materials, USA. 
UV-Spectrophotometer: SpectraMax 190 Microplate Reader UV Spectrophotometer, 
Molecular Devices Corporation, California, USA. 
Vortex mixer: Vortex Genie 2™, Bender & Hobein AG, Zurich, Switzerland. 
 
4.3 Computer programs 
HPLC: Empower™ 3 Software, Build 3471, Waters, 2010. 
Particle Size Analysis and Zeta Potential Measurement: Malvern Zetasizer Software for the 




UV microplate reader: SoftMax Pro software version 5, Molecular Devices Corporation, 
California, USA. 
 
4.4 Experimental section 
When working with the cytotoxic drug DOC, precautions were made not to be exposed to the 
drug. Thus, the dry powder was always handled in a dedicated LAF-bench, and DOC-
containing containers were kept sealed when handled outside the LAF-bench. 
 
4.4.1 DOC stock-solution 
A DOC stock-solution containing 20 mg/mL DOC was prepared prior to making the HPLC 
standard curve (Section 4.5.3) and for accurate transfer of the aimed amount of DOC to the 
liposomal formulations (Section 4.4.2). DOC was weighed in a small sample tube on an 
analytical balance (Sartorius CP225D) placed in the LAF-bench, and the locked vial control 
weight in a more precise balance (Sartorius BP211D) before transferred to a volumetric flask 
and dissolved in 10 mL methanol. The DOC stock-solution was kept in the refrigerator at 4 °C 
when not in use. 
 
4.4.2 Preparation of liposomes with DOC 
The DOC-liposomes were prepared through three distinct steps: 1) lipid film formation using 
the thin-film hydration method, 2) lipid film hydration, as shown in Figure 12, and finally, 3) 
size reduction. The first step assured an even distribution of DOC in the lipid membrane, 
hydration the lipid film with water was the liposome forming step, whereas the sonication 





Figure 12: A schematic presentation of the two first steps applied when preparing liposomes; the lipid film 
formation step evaporating the organic solvent and the lipid hydration step leading to the formation of a liposomal 
dispersion. 
 
4.4.2.1 Lipid film formation 
The thin-film hydration method (Bangham et al., 1965) was applied for making the lipid films. 
First, 200 mg of the selected lipid was transferred to a 100 mL round bottom flask, and 1 mL 
of the DOC stock-solution (corresponding to 20 mg DOC) was transferred by pipetting and 
mixed with the lipids. To dissolve the lipids, chloroform and/or methanol were added in 
different ratios depending on the lipids applied to dissolve the lipid(s) and the DOC. 
The round bottom flask containing the lipid-drug solution was placed in a Büchi Rotavapor R-
124 on Büchi Water Bath B-480 (Büchi laborteknik, Switzerland) with a Büchi Vac V-500 
vacuum pump system and Büchi Vacuum Controller B-721 to control the pressure under the 
rotavapor process. To keep the lipids fluid and homogeneous, the water bath was preheated and 
kept at a temperature higher than the lipids Tm (usually 44 °C). The pressure and temperature 
were adjusted to assure that the solutions did not boil but evaporate. The pressure was decreased 
gradually from 1005 mBar to 55 mBar, at a rotation speed of 80 rpm, that was gradually 





4.4.2.2 Lipid film hydration 
The lipid film was hydrated with 10 mL preheated filtrated (0.2 µm) distilled water to form a 
liposomal dispersion containing 20 mg/mL lipid and 2 mg/mL DOC. The flask was vortexed 
to properly disperse and dislodge the lipid film, making sure that all lipid and drug was detached 
from the walls of the flask. The water added kept the same temperature as the lipid film. The 
liposomal dispersions were stored at 4 °C overnight before sonication. 
 
4.4.2.3 Size reduction of liposomes 
A probe sonicator (Sonics Vibra Cell high intensity ultrasonic processor VS 754 750 Watt with 
Ultrasonic processor, CVR 234 Converter with a Probe 19 mm, Sonic and Materials, USA) was 
used to reduce the size of the liposomal dispersion. Prior to sonication, the liposomal dispersion 
was brought to room temperature and transferred to a 45 mL falcon tube. The sonication probe 
was positioned in the centre of the tube making sure that it did not touch the walls. The tube 
was placed in an ice bath to prevent the sample from getting warm. Amplitude was set to 40 %. 
The duration of the sonication varied with the lipid composition and judged from the turbidity 
of the preparation and finally size measurements (Section 4.5.1). In general, sonication runs 
were between 0.5 and 4 minutes with a one-minute cooling break between each run, to avoid 
overheating. A liposome size around 100 nm was targeted.  
 
4.4.3 Removal of unentrapped drug from the liposomes by centrifugation 
The liposomal dispersions were allowed to equilibrate in the refrigerator overnight, before 
separating the unentrapped drug from the liposomes through centrifugation. The liposoma 
dispersion was separated in 15 mL falcon tubes, and centrifugated at 3000 rpm (min-1) 
(corresponding to 1800 g) for 20 minutes at 25 °C in a Biofuge stratos (Heraeus Instruments, 
Oslo) with Heraeus rotor #3048 and #3047. The centrifuge needed one minute to increase the 
velocity from 0-3000 rpm, and one minute in the end to decrease the velocity from 3000-0 rpm. 
The supernatant was transferred to new 15 mL falcon tubes and further examined, as described 





4.5 Liposomal characterization 
A Zetasizer Nanoseries ZS (Malvern, UK) was used to determine both the size distributions 
and zeta potential of the prepared liposomal dispersions. 
 
4.5.1 Liposome size determination 
The liposomal dispersion was homogenized by vortexing and diluted 1:25 (v/v) with freshly 
filtrated (0.2 µm) distilled water before size measurement. The test cuvette (12 mm square 
polystyrene cuvettes, Malvern Zetasizer Nano Series) was rinsed thoroughly with 1 mL ethanol 
and 2 mL filtrated (0.2 µm) distilled water before and after measurement. Each sample was 
analysed in triplicate. The measurements gave information of the average intensity weighted 
size distribution of the liposomes and polydispersity index (PI). 
 
4.5.2 Determination of zeta potential 
The liposomal dispersions were homogenized with a vortex machine and diluted 1:20 (v/v) with 
filtrated (0.2µm) tapped water before zeta potential measurement. The disposable folded 
capillary cells (Malvern Zetasizer Nano Series) were rinsed thoroughly with ethanol, filtrated 
tapped water and flushed with 1 mL of the sample before filling the cuvette with the sample to 
be analysed. A 1 mL syringe was used to clean and fill the cells with the sample. The 
measurement was set to 3 cycles and 100 runs. Each sample was measured twice. 
 
4.5.3 HPLC: determination of DOC recovery 
The DOC concentration in the liposomal dispersions both before and after centrifugation 
(supernatant) was quantified by high performance liquid chromatography (HPLC) using a 
Waters e2795 Separations Module connected to a Waters 2489 UV/Visible detector and a C-
18 column: XSELECT CSH column XP, 2.5 µm 3.0x75 mm (Waters, Dublin, Ireland). 
The method applied had a 12 minutes run time. The sample volume injected varied were 10 µL. 




contained Milli-Q-water with 0.1 % formic acid and Mobile phase B, contained acetonitrile 
with 0.1 % formic acid. The gradient flow condition applied is given in Table 5. Temperature 
of both the column and sample were set to 25 ± 1°C. The retention time of the DOC peak was 
at 7.74 minutes and the detection wavelength applied using the Waters 2489 UV/Visible 
detector was at λ = 232 nm. 
Table 5: Gradient flow conditions for mobile phase A and B applied in the DOC-HPLC method. 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0.00 80.0 20.0 
8.00 10.0 90.0 
10.00 10.0 90.0 
10.10 80.0 20.0 
12.00 80.0 20.0 
 
The standard curve was created from DOC standards with known concentrations in the range 
of 0.5-1200 µg/mL. The calibration standard curve showed linearity in the range of 0.50-1200 
µg/mL, with a R2=0.9986 (Figure 13). The amount of DOC in the liposomal formulations was 
subsequently quantified based on the standard curve. 
 
Figure 13: The docetaxel standard curve obtained using HPLC. 
 
The eluted DOC peak had a retention time of approximately 7.7 minutes, as illustrated in Figure 
14. 

















Figure 14: A typical chromatogram obtained from the HPLC when quantifying the DOC content.  
 
Before DOC quantification, the DOC-liposomal dispersion was diluted with methanol to reach 
concentrations within the span of the calibration curve. Methanol disrupt the liposomal 
structure, and forms a solution containing DOC and PLs that were separated when injected onto 
the HPLC for accurate quantification of DOC. The samples were prepared in quintuplicate (five 
preparations of each sample) in HPLC vials and every sample was injected twice.  
The amount of DOC recovery in the supernatant was compared with the amount of DOC present 
in the total sample before centrifugation to calculate the recovery of DOC in supernatant. The 
recovery of DOC was calculated by Equation 1. 
Equation 1: 
Recovery of DOC (%) = DOC concentration in supernatant (µg/mL)
DOC concentration in total sample (µg/mL)
×100 % 
 
4.5.4 Phospholipid assay – determination of the PL recovery 
In order to determine the recovery of phospholipids (PL) in the liposome-containing 
supernatant after centrifugation (Section 4.4.3), the amount of PL was determined both in the 
liposomal dispersions before centrifugation and the supernatant after centrifugation. For this, 
the phosphatidylcholine assay (PC-assay) was applied using a method obtained from Bartlett 
(Bartlett, 1959) with some modifications (Naderkhani et al., 2015). PLs such as PC, PE and PG 




phosphorus in the liposomal dispersions and hence give an estimation of amount lipid in the 
liposomal formulations. This was further used to adjust for loss of lipid when calculating the 
entrapment efficiency in Section 4.5.5. 
The reagent solutions used in the PC-assay (Bartlett, 1959; Naderkhani et al., 2015) are 
described in Section 4.1.3.2. In addition to these solutions, the samples (liposomal dispersions), 
the phosphorous standards for the phosphorous standard curve and the phospholipid (PL) 
reference samples were prepared: 
The liposomal formulations were diluted with distilled water, transferring 50 µL liposomal 
sample to a volumetric flask and adding distilled water to a total volume of 10 mL, giving a 
final lipid concentration of approximately 0.1 mg/mL. 
Phosphorus standard solutions were prepared to make a standard curve. A phosphorus standard 
solution with a concentration of 19.5-20.4 µgPhos/mL (Sigma Aldrich Chemie GmbH, 
Steinheim, Germany) was added to glass tubes and diluted with distilled water to reach a total 
volume of 1 mL and the following phosphorus concentrations: 1, 2, 3, 4, 5 and 8 µg/mL.  
Reference PL-samples were made by transferring 7.5 mg SPC into a 50 mL volumetric flask 
and filling it up with 50 mL 0.5M HCl. The PLs were vortexed until completely dispersed and 
left to stir overnight, where after the samples appeared opaque. 
All solutions, including the phosphorus standard solutions, the blank medium (distilled water), 
reference PL-samples and the liposomal dispersions were prepared in triplicates and 3 x 1 mL 
were transferred to glass tubes before adding 0.5 mL H2SO4 10N, to a total volume of 1.5 mL. 
The glass tubes were covered by marbles, and then heated in the oven at 160 °C for three hours. 
After cooled down to room temperature, 2 drops of 30 % (v/v) hydrogen peroxide (H2O2) were 
added to each sample, before heated at 160 °C for 1.5 hours. In the final step, and after cooled 
down to room temperature, 4.6 mL ammonium molybdate 0.22 % (v/v) and 0.2 mL Fiske 
SubbaRow reducer solution were added to the samples. Samples were mixed thoroughly by 
vortexing before heating the samples at 100°C for 7 minutes. 
Each sample was measured in triplicate, transferring 0.2 µL sample into three wells of a 96 well 
plate. Absorbance were measured with a UV spectrophotometer (SpectraMax 190, Molecular 




A phosphorous standard curve was prepared for every experiment, after withdrawing 
absorbance values measured for the blanks (distilled water). The 96 well plates were measured 
both on the same day as the assay was performed and the day after. The best results were 
obtained the day after the PC-assay, judged from the R2-value of the standard curve, and 
therefor applied for further calculation of the PL recovery in the liposomal formulations. 
The calibration standard curve showed linearity in the range of 1-8 µg/mL with R2= 0.9972, 
R2= 0.997, R2= 0.9989, R2= 0.9976 and R2= 0.999 in the different experiments when 
absorbance was measured the day after sample preparation. A representative standard curve is 
given in Figure 15. 
 
Figure 15: One of the phosphorous standard curves obtained from the PC-assay. 
 
From the phosphorous standard curve (Figure 15), the phosphorous content of the reference 
PL-samples was quantified, and the ratio between the known lipid concentration (7.5 mg/50mL 
=0.148 mg/mL) and the measures mean phosphorous concentration calculated from the 
phosphorous standard curve. From these information, the PL content of the liposomal 
formulations were calculated, as given in Equation 2. 
Equation 2: 
PL conc. in liposome = Phosphorous conc. in liposome ×(
PL conc. reference PL-sample
Phosphorous conc. reference PL-sample
) 





















The ratio between the quantified PL-content in liposomal dispersion before centrifugation (total 
sample) and after centrifugation (in the supernatant), expressed as PL recovery, was then 
calculated using Equation 3. 
Equation 3:  
PL recovery (%) =(
PL in supernatant (µg/mL)
PL in total sample (µg/mL)
)× 100 %  
 
4.5.5 Liposomal DOC entrapment determination 
Finally, the drug entrapment efficiency (EE %) was calculated, adjusting for the liposomes lost 
during centrifugation, that is correlated with the PL recovery found using the PC-assay (Section 
4.5.4). Bigger liposomes or liposome-aggregated will, due to the centrifugal forces, follow the 
drug precipitate into the pellet, and thus the lipid lost should be accounted for, as a low lipid 
recovery means that liposomal entrapped DOC is lost in the pellet during centrifugation (see 
section 4.5.4). The calculation of drug entrapment, adjusting for the liposome lost during 
centrifugation is shown by Equation 4. 
Equation 4: 
EE (%) =
Recovery of DOC (%) 
Recovery of phospholipid (%)
 x 100 % 
 
Drug load capacity gives the drug:lipid weight ratio, calculated from the measured amount of 
DOC (Section 4.5.3) and lipids (Section 4.5.4) present in the liposomal formulation after 
removal of the unentrapped drug by centrifugation, as measured in the supernatant. The 
calculation is shown by Equation 5. 
Equation 5: 
Drug load capacity =
DOC concentration in supernatant (µg/mL)
PL concentration in supernatant (µg/mL)
 * 





4.6 Preparation of DOC-lipid solutions – DOTAP study 
In the final part of the study, the DOTAP study, not only DOC was added as stock-solutions 
(Section 4.4.1), but also DOTAP and SPC were prepared in known concentrations using the 
same solvents as in the previous studies. The exact volume was pipetted out from these 
solutions to assure that the actual weight ratio between the lipids and DOC was exactly as 
intended (Table 6). 
Table 6: Preparation of solutions with DOC, DOTAP and SPC for the DOTAP study. 
Liposomal 
formulation 
(DOTAP % (w/w) 
of total lipid) 
Volume DOC  
stock-solution  
(20 mg/mL in 
methanol) 
Volume DOTAP stock-





(200 mg/mL in 
methanol) 
1 (0 %)  
 
1500 µL 
- 1 mL 
2 (10 %) 250 µL 900 µL 
3 (20 %) 500 µL 800 µL 
4 (30 %) 750 µL 700 µL 
5 (50 %) 1250 µL 500 µL 
 
The solutions were mixed in injection vials and sealed with a lid and frozen to -80°C until 
further processing following the normal procedure described in Section 4.4.2 and 4.4.3. The 






5 Results and Discussion 
The focus of this project has been to investigate how liposomal compositions affect the DOC 
entrapment. The project was separated into four sub-parts that were interconnected. The first 
part was the “Pilot project”, where we established the methods used in this thesis, validating 
the reproducibility of the methods applied by conducting repeating experiments with two 
different liposomal formulations.  
The second part was the “Screening study”, where 14 different lipid combinations in liposomal 
formulations were screened with the purpose to identify what lipids should be preferred or 
avoided to obtain the optimal DOC entrapment efficiency and drug load. The formulations that 
showed best properties with regard to entrapment efficiency were brought to the third part, the 
“Optimization study”, in which we investigated if an increased DOC:lipid ratio could increase 
the drug entrapment of these formulations. In the fourth and final part, the “DOTAP study”, the 
best liposomal formulation, containing SPC and DOTAP, was further investigated using 
different DOTAP concentrations. 
 
5.1 Pilot project 
To validate the liposome preparation method, and the suitability of the methods applied for 
quantifying DOC and PL, a Pilot project with two different liposomal formulations was carried 
out. These liposomes were made from SPC and SPC and Chol (8:2 w/w), respectively. Both 
formulations contained DOC in a 1:10 (w/w) ratio with the lipids and were prepared as 
described in Section 4.4. Both formulations were prepared in triplicates. 
Since the method applied during liposome preparation should be suitable for comparing 
different liposomal formulations and their potential of entrapping DOC in the liposomal 
membrane, we first had to look at the reproducibility of the method and also whether or not the 
liposomes were of a suitable size and size distribution, enabling good separation of the 
unentrapped drug and liposomes, assuring the liposomes remaining in the supernatant during 
the centrifugation procedure, and trapping the precipitated drug in the pellet. For this to happen, 
the liposomes should be sufficiently small, and as the rigidity of the liposomal bilayer will differ 




of < 100 nm was not predefined but judged by the appearance of the liposomal dispersions that 
becomes less opaque as the liposome size was reduced. In Table 7, the final sonication time 
applied for the three batches of the two “Pilot liposomal formulations” are given together with 
their size and PI values and measures of the zeta potential. 







(nm ± SD) 
PI  
(AU ± SD) 
Zeta potential 
± SD 
SPC A (3 min) 79.27 ± 0.54 0.24 ± 0.01 -0.11 ± 0.36 
B (2 min) 85.77 ± 0.36 0.23 ± 0.01 -0.12 ± 0.06 
C (2 min) 80.43 ± 0.19 0.25 ± 0.01 -0.35 ± 0.05 
SPC:Chol 
(80:20 w/w) 
A (3 min) 63.54 ± 0.38 0.22 ± 0.00 -1.88 ± 0.52 
B (3 min) 58.28 ± 0.40 0.21 ± 0.01 -1.98 ±0.22 
C (3 min) 57.58 ± 0.26 0.20 ± 0.01 -2.56 ± 0.50 
 
The three parallels of the SPC liposomes showed a mean average diameter of 81.82 ± 3.46 
(Figure 16), and mean zeta potential was -0.19 ± 0.13. The three parallels of the SPC:Chol 
liposomes showed a mean average diameter of 59.80 ± 3.26 (Figure 16) and mean zeta potential 
was -2.14 ± 0.37. Although some intra variability in between the liposomal formulations, the 
results were satisfying with respect to reproducibility. 
 
Figure 16: Size distribution and mean entrapment efficiency of SPC and SPC:Chol liposomes. The value denotes 






























































The success of separating liposomes and free drug was judged by visually inspecting the vial 
after centrifugation, and finally from the results obtained from the PC-assay, quantifying the 
PLs present in the liposomal dispersion before (total sample) and after (supernatant). These 
results are given in Table 8. The recovery of PL in the supernatant was higher for the SPC:Chol 
liposomes than for the SPC liposomes, something that might be explained by smaller size of 
these liposomes. However, this variation in PL recovery was found acceptable, and the method 
kept unchanged for further studies. 





(nm ± SD) 
PI  
(AU ± SD) 
PL concentration (mg/mL) PL recovery 
(% ± SD) Total sample Supernatant 
SPC 79.27 ± 0.54 0.24 ± 0.01 22.21 18.48  
85.9 ± 0.05 85.77 ± 0.36 0.23 ± 0.01 21.83 18.17 
80.43 ± 0.19 0.25 ± 0.01 19.75 18.00 
SPC:Chol 
(80:20 w/w) 
63.54 ± 0.38 0.22 ± 0.00 17.44 16.95  
97.3 ± 0.04 58.28 ± 0.40 0.21 ± 0.01 17.16 16.09 
57.58 ± 0.26 0.20 ± 0.01 16.49 16.67 
 
The liposomes lost in the pellet were considered when calculating the drug entrapment 
efficiency (Equation 4), as shown in Table 9. Both the higher entrapment efficiency than 100 
% and a higher PL-concentration in the total sample before centrifugation, than expected from 
the amount of lipids added (20 mg/mL and a 16 mg/mL PL concentration in the total sample 
for the SPC liposomes and the SPC:Chol liposomes, respectively), indicates that the real PL 
recovery was higher than calculated from the measured results from the PC-assay. Thus, the 
real DOC entrapment might be corresponding to a value somewhere between the measured 
DOC recovery in the supernatant and the calculated DOC entrapment values, that takes into 





Table 9: Drug content and entrapment of DOC in the “Pilot liposomal formulations”. 
Liposomal 
formulation 
DOC concentration (µg/mL) DOC 
recovery (%)  
EE (%)* 
Total sample Supernatant 
SPC 195.59 ± 2.35 184.64 ± 3.00 94.4 113.5 
190.29 ± 4.72 175.19 ± 2.23 92.1 110.6 
213.07 ± 3.61 206.85 ± 2.86 97.1 106.5 
SPC:Chol  
(80:20 w/w) 
226.91 ± 5.99 47.12 ± 1.31 20.8 21.4 
211.56 ± 8.52 53.04 ± 2.43 25.1 26.7 
218.72 ± 8.29 59.19 ± 1.19 27.1 26.8 
* DOC entrapment (%) calculated when taking into account the PL lost during centrifugation. 
 
The mean EE (%) of the SPC liposomal formulations was 110 % as shown in Table 9. The 
reason why the entrapment exceeds 100 % could be explained by the correction of lipid content. 
The mean entrapment efficacy of DOC was much lower for the SPC:Chol liposomes and around 
25 %, as shown in Figure 16. Thus, it seems that Chol is expelling the DOC from the liposomal 





5.2 Screening study: Liposomal lipid composition 
After validating the method in the Pilot project, the second step in the project was to screen 
different lipids in a liposomal DOC formulation to optimize entrapment of DOC. The 14 
liposomal formulations included in the study had different lipid composition, but the same 
drug:lipid ratio of 10:1 (w/w). Information on the liposomal formulations, the ratio of lipid(s) 
investigated, and the organic solvent applied for the lipid film preparation are summarized in 
Table 10. 
Table 10: Screening of liposomal formulations with different lipid compositions. No. = Formulation number. Tm 
= transition temperature. 
No. Lipid composition Lipid ratio 
(w/w) 
Tm °C Solvent 
1 SPC 100 -20 to 30 Methanol * 
2 SPC:Cholesterol 80:20  Chloroform:methanol (2:1 v/v) * 
3 SPC:DOPE 80:20 -16 Chloroform:methanol (2:1 v/v) * 
4 SPC:DOPC 80:20 -20 Methanol * 
5 SPC:DSPE-
PEG2000 
80:20 65 Chloroform 
6 SPC:DOTAP 80:20  Chloroform:methanol (2:1 v/v) * 
7 SPC:Ceramide C6 80:20  Chloroform 
8 SPC:Ceramide C12 80:20  Chloroform 
9 SPC:DPPG 80:20 41 Chloroform:methanol (2:1 v/v)* 
10 SPC:DMPG 80:20 23 Chloroform:methanol (2:1 v/v) * 
11 SPC:DMPC 80:20 24 Methanol* 
12 SPC:DMPE 80:20 50 Chloroform 
13 SPC:POPC 80:20 -9 Chloroform:methanol (4:1 v/v) 
14 SPC:POPE 80:20 25 Chloroform:methanol (6:1 v/v) 
*(Flaten, 2003) 
 
The amount of organic solvent varied and was depended on the solubility of the different lipids 
used. Another factor varied was the temperature of the water bath, which were increased to 
exceed the Tm of the different lipids (Li et al., 2015; Laouini et al., 2012). 
During sonication, the span of sonication was judged empirically from the appearance of the 
liposomal dispersions. The liposomal dispersions were visually inspected every 30 seconds to 
look at the transparency of the dispersions and evaluate the size. The dispersions went from 
being opaque and white to more transparent as they became smaller. Since this formulation is 




(Harashima et al., 1994; Allen and Cullis, 2004) and preferably around 50-100 nm (Bozzuto 
and Molinari, 2015; Kumari et al., 2016). The size was measured before centrifugation to assure 
an average diameter around 100 nm, but the polydispersity was very high. Hence, appearance 
was a decisive factor for sonication time. After purification, the average diameter and PI 
showed an acceptable range of the liposomal formulations. The different liposomal 
formulations required different sonication times for getting smaller, and therefore it was 
difficult to standardize the sonication time. 
The liposomal characteristics of liposomal formulation 1-14 are presented in Table 11. All 
formulations contained 200 mg of lipid and 20 mg of DOC. 







(nm ± SD) 
PI 
(AU ± SD) 
Zeta potential 
± SD 
1* SPC 3, 2, 2 min 81.82 ± 3.46 0.24 ± 0.01 -0.19 ± 0.13 
2* SPC:Chol 3, 3, 3 min 59.80 ± 3.26 0.21 ± 0.01 -2.14 ± 0.37 
3 SPC:DOPE 1.5 min 91.31± 0.55 0.24 ± 0.00 -5.46 ± 0.48 
4 SPC:DOPC 3 min 78.11 ± 0.50 0.28 ± 0.01 -2.59 ± 0.16 
5 SPC:DSPE-
PEG2000 
0.5 min 97.55 ± 0.24 0.36 ± 0.01 -3.31 ± 0.34 
6 SPC:DOTAP 3 min 77.97 ± 0.25 0.29 ± 0.00 76.28 ± 0.90 
7 SPC:CC6 2 min 77.35 ± 0.52 0.24 ± 0.00 -1.87 ± 0.04 
8 SPC:CC12 2 min 96.93 ± 0.83 0.42 ± 0.06 -1.33 ± 0.07 
9 SPC:DPPG 0.5 min 103.67 ±0.71 0.24 ± 0.01 -31.52 ±0.62 
10 SPC:DMPG 0.5 min 98.69 ± 0.82 0.25 ± 0.00 -31.90 ± 0.40 
11 SPC:DMPC 0.5 min 109.37 ± 0.68 0.21 ± 0.00 -2.29 ± 0.05 
12 SPC:DMPE 4 min 182.57 ± 8.98 0.86 ± 0.03** -6.63 ± 0.24 
13 SPC:POPC 4 min 81.48 ± 0.26 0.21 ± 0.00 -0.34 ± 0.10 
14 SPC:POPE 2 min 86.03 ± 0.93 0.32 ± 0.02 -5.60 ± 0.48 
*n=3 (average of the results in the Pilot project) ** The estimated diameter of the liposome vesicles is too 
polydisperse, that means the PI values that exceeds 0.7 are not valid. 
 
The average size of the different liposomal formulations in the Screening study was around 100 
nm ranging from 77-109 nm, with the exception of SPC:Chol liposomes which were 60 nm and 
SPC:DMPE which were 183 nm as shown in Figure 17. 
The liposomal formulations were observed to exhibit a smaller size and lower PI after 




DOC in the supernatant (Pereira et al., 2016). Thus, the size and zeta potential measurements 
conducted for total lipid dispersion during sonication were only applied as a guidance for 
whether to stop the sonication and not included in the final results, as the results obtained after 
centrifugation (Table 11 and Figure 17) was considered more accurate and reliable. 
 
Figure 17: Liposomal size distributions in the Screening study. 
 
PI is a measure of heterogeneity, or the width of the distribution of particles (Woodbury et al., 
2006). Small values of PI (< 0.2) indicate homogenous distribution while larger PI values (> 
0.2) indicates high heterogeneity and broad distribution of particles. The PI value should not 
exceed 0.7 because in that case the liposomal formulations is too polydisperse and cannot be 
trusted (Malvern, 2013). 
The majority of the liposomal formulations displayed a PI < 0.3, which indicate that the 
measurement with the Malvern Zetasizer is a suitable method for these samples. SPC:Ceramide 











































indicate that they show a broader polydispersity, but were still below 0.7. However, the 
SPC:DMPE (No. 12) displayed a PI of 0.86 and hence it was found too polydisperse. 
 
Figure 18: Liposomal charge in the Screening study. 
 
The majority of the liposomal formulations carried a slightly negative charge, as shown in 
Figure 18. The head group of the lipids decides the charge (Kraft et al., 2014). The liposomal 
formulations composed of PE or PC were almost neutral, as expected as these head groups are 
neutral, as seen in Table 1. The SPC:DPPG (No. 9) and SPC:DMPG (No. 10) carried a high 
negative charge around -30 mV, as expected since the PG head group carry a net negative 
charge as seen in Table 1 and hence contributes to the highly negative zeta potential. The 
SPC:DOTAP (No. 6) was the only liposomal formulation in this study found to have a positive 
charge, as expected because DOTAP is a cationic lipid (Zhi et al., 2018). 
Both SPC and SPC:Chol liposomes were slightly negative charged, and close to neutral, as 
expected since either SPC or Chol bear a charge. Yang et al. (2007) prepared liposomes with 

















































coinciding with our results, even though the lipid ratio and drug were not the same (Yang et al., 
2007). 
Neutral liposomes have a lower tendency to be cleared by the MPS but have a higher tendency 
to aggregate. Both a negative and a positive charge contributes to reduce tendency to aggregate 
and hence increase the stability (Kraft et al., 2014), but on the contrary, a negatively and a 
positively charge increases the chance of being opsonized and cleared by the MPS and hence a 
shorter period of the in the circulation after being administrated (Lian and Ho, 2001; Allen and 
Cullis, 2013).  
The results of entrapment efficiencies and drug:lipid ratio for the liposomal formulations are 
presented in Table 12. Drug recovery is the ratio between DOC concentrations in the 
supernatant after centrifugation divided by the total DOC concentration before centrifugation, 
determined by HPLC. The DOC concentration was adjusted by the PL recovery to compensate 
for variable PL recovery presented as entrapment efficiency (EE %). The drug load capacity 
represents how much DOC that is associated with the liposomes (the drug:lipid ratio), and gives 
a more comparable measure of the drug load in the liposomal membrane, as it is not associated 
with the initial drug:lipid ratio applied in the formulation (Pereira et al., 2016).  
Table 12: Liposomal characteristics of 14 liposomal formulations investigated in the Screening study. 
No. Lipid 
composition 
DOC recovery in 
supernatant (%) 
PL recovery in 
supernatant (%) 
EE (%) DOC:lipid 
ratio (w/w) 
1 SPC 94.5 ± 0.03 85.9 110.2 ± 0.04 0.104 ± 0.98 
2 SPC:Chol 24.3 ± 0.03 97.3 25.0 ± 0.03 0.040 ± 0.49 
3 SPC:DOPE 69.9 84.4 82.5 0.079 
4 SPC:DOPC 48.0 89.3 53.8 0.051 
5 SPC:DSPE-
PEG2000 
64.4 95.1 67.7 0.058 
6 SPC:DOTAP 101.7 88.8 114.6 0.122 
7 SPC:CC6 15.7 89.8 17.5 0.027 
8 SPC:CC12 20.8 89.3 23.3 0.039 
9 SPC:DPPG 65.2 90.7 71.8 0.064 
10 SPC:DMPG 92.3 95.9 96.2 0.089 
11 SPC:DMPC 48.7 84.6 57.6 0.057 
12 SPC:DMPE 39.3 99.2 39.6 0.041 
13 SPC:POPC 53.8 95.7 56.3 0.062 
14 SPC:POPE 45.9 97.4 47.1 0.052 
* Liposomes that included cholesterol (Chol), DOTAP, Ceramide C6 (CC6) and Ceramide C12 (CC12) had their 
lipid content adjusted for in the calculations; lipid amount = phospholipid content * 1.25. This since these lipids, 





The recovery of DOC after purification ranged between 16-102 % for the 14 different liposomal 
formulations. The drug recovery and entrapment efficiency of formulation no. 2, 4, 7, 8, 11, 12 
and 14 was rather low, all of them with recovery of DOC below 50 % and <60 % EE. All 
formulations showed lipid recoveries ranging between 84 and 100 %, hence the lipid loss during 
purification of liposome cannot be responsible for the amount of DOC that was lost during 
purification. A possible explanation for this could be that DOC was not fully incorporated in 
the liposomal bilayer, but rather associated with the outer surface and hence lost during 
centrifugation leading to a reduction in entrapment efficiency. This was also suggested by 
Pereira et al. (2016) which made liposomal formulations of DOC, but with non-comparable 
compositions of the liposomes. In their study, a liposomal formulation composed of 
DOPC:Chol prepared with a molar ratio of 100:50 with a lipid:drug ratio of 40:1, 20:1 and 10:1, 
respectively, showed a maximum entrapment efficiency around 90 % for all three lipid:drug 
ratios (Pereira et al., 2016). 
The 14 different liposomal formulations showed highly varying results with respect to 
DOC:lipid ratio, as shown in Table 12. The SPC (No. 1) and SPC:DOTAP (No. 6) liposomal 
formulations showed that the amount of DOC that was associated with the liposomes was 
approximately 0.1 DOC/1 lipid (w/w), which was consistent with the initial drug:lipid ratio of 
1:10 (w/w). The SPC:DMPG (No. 10) showed a DOC:lipid ratio of 0.089 DOC/1 lipid (w/w) 
which was slightly lower than the SPC and the SPC:DOTAP liposomal formulation. 
The SPC:Chol (No. 2), SPC:Ceramide C6 (No. 7) and SPC:Ceramide C12 (No. 8) liposomal 
formulations showed the lowest DOC:lipid ratio of all 14 liposomal formulations, all with a 
DOC:lipid ratio of ≤ 0.040 DOC/1 lipid (w/w). These results were consistent with the low 
entrapment efficiency of the same liposomal formulations.  
The entrapment of DOC of the 14 different liposomal formulations ranged between 18 % and 





Figure 19: Entrapment efficiency of liposomal formulation 1-14 in the Screening study. 
 
As shown in Figure 19 the entrapment of DOC varied a lot. The entrapment of DOC is 
dependent on the properties of the acyl chains of the PLs in the liposome and DOCs partition 
coefficient and polarity. Because of DOCs lipophilic nature it will reside in the fatty acyl chains 
of the liposome, and hence properties of the PLs used is a decisive factor for entrapment 
(Bozzuto and Molinari, 2015).  
This study showed no correlation between saturation of the lipids and entrapment efficiency. 
SPC:DOTAP (No. 6) is unsaturated, as shown in Figure 6 and has the highest entrapment 
efficiency, but SPC:DMPG (No. 10) is unsaturated (Table 1) and has entrapment around 100 
%. Formulation no. 3, 4, 6, 7, 8, 9, 13 and 14 were all unsaturated and displayed varying 
entrapment efficiency in the range of 18-115 %, and formulation no. 10, 11 and 12 is composed 
of saturated lipids and show an entrapment ranging from 40-96 %. 
Immordino et al. (2003) investigated different liposomal formulations of DOC, but with non-
comparable compositions of lipids. In their study it was observed that changing an unsaturated 
lipid (egg PC) with saturated lipids decreased the encapsulation efficiency. This was not found 









































entrapment efficiency. They also observed that a higher amount of Chol or an increased 
DOC:lipid molar ratio affected the encapsulation efficiency negatively (Immordino et al., 
2003).  
Pereira et al. (2016) reported that liposomes composed of unsaturated lipids showed the highest 
DOC loading compared to saturated lipids. They used other lipid combinations in which are 
non-comparable with this study (Pereira et al., 2016). In this study we screened 14 different 
lipid combinations, in which we included 1-2 lipids in the different liposomal formulations, 
while both Immordinio et al. (2003) and Pereira et al. (2016) included more than 2 lipids in 
their liposomes. Hence it is several factors that affect how well DOC is incorporated and 
becomes a part of the liposomal membrane, and it is difficult from our findings to conclude it 
saturation affects the entrapment efficiency. It could appear like that DOC have a higher affinity 
for cationic lipid blends as compared to the non-charged and negative charged. This has also 
been described for other anticancer agents with lipophilic properties, like Camptothecin (Sætern 
et al., 2004). 
We evaluated if different lengths of the fatty acids and variety head group of the PLs used in 
the different liposomal formulations could affect the entrapment of DOC. The head group of 
PLs determine the charge. Both PC and PE are non-charged (Kraft et al., 2014) as shown in 
Figure 5. In this study we used four different PLs with PC: SPC (No 1), DOPC (No. 4), DMPC 
(No. 11) and POPC (No. 13) which showed entrapment of 110, 54, 58 and 56 %, respectively. 
Interestingly, the liposomal formulations composed of DOPC, DMPC and POPC displayed a 
rather similar entrapment of DOC, even though they had different length and saturation of the 
fatty acids, where DMPC have saturated C14 chains, DOPC have unsaturated C18 chains, and 
POPC have one C18 saturated and one C18 unsaturated chain, as shown in Table 1. 
We used four different PLs with PE as head group: DOPE (No. 3), DSPE (No.5), DMPE (No. 
12) and POPE (No. 14) which showed varying entrapment of DOC with 83, 68, 40 and 47 %, 
respectively. Hence, for these liposomal formulations, it seems like properties of the fatty acids 
was determinant of entrapment.  
PG is a negatively charged head group (Kraft et al., 2014), as seen in Figure 5. We used two 




96 %, respectively. In this case it seems like a shorter fatty acyl chain gives higher entrapment, 
as saturation is the same for both dipalmitoyl in DPPG and dimyristoyl in DMPG (Table 1). 
When comparing lipids with the same fatty acyl acids, but with different head groups in 
between the different liposomal formulations, such as DMPG (No. 10), DMPC (No. 11) and 
DMPE (No. 12), the entrapment decreases from 96 % with the PG group, to 58 % with the PC 
group, to 40 % with the PE group. These lipids have the same fatty acyl group: dimyristoyl 
which are saturated with 14 carbons, as seen in Table 1. The same trend could be seen with 
POPC (No. 13) and POPE (No. 14) where entrapment decreases from 56 % with PC to 46 % 
with PE. These two lipids have the same fatty acyl group: palmitoyl-oleyl which have one 
saturated 16 carbon chain and one unsaturated 18 carbon chain. From these observations, it 
could seem like the head group of PLs affects entrapment in the following order: PG > PC > 
PE. However, this is not the case with the fatty acid dioleoyl in DOPE (No.3) and DOPC (No. 
4) where DOPE have a higher entrapment of DOC with 83 % compared to DOPC with 54 %. 
The liposomal formulations which contained ceramides showed poor entrapment of DOC. 
Ceramide C6 (No. 7) with a C6 fatty acyl chain, shown in Figure 7, showed an entrapment of 
18 %, while ceramide C12 with a C12 fatty acyl chain, shown in Figure 8, showed a slightly 
higher entrapment with 23 %.  
The liposomal formulation containing Chol (No. 2) also showed a poor entrapment of DOC 
with 25 %. Previous studies have found that Chol in liposomal formulations with hydrophobic 
drugs (paclitaxel and DOC) exhibits a negative effect on encapsulation efficiency (Crosasso et 
al., 2000; Immordino et al., 2003) and can be explained by Chol occupying the hydrophobic 
space in the membrane (Chen et al., 2017). However, Immordino et al. (2003) showed that 
inclusion of a small amount of Chol did not have a negative effect on encapsulation efficiency 
of DOC, but in concentrations over 30 mol% the encapsulation efficiency and stability 
decreased (Immordino et al., 2003). In our case, the Chol concentration was ~33 mol%, and 
therefore our results correspond well with the work of Immordino and colleagues. 
Chen et al. (2017) made liposomes with egg PC:Chol:DSPE-PEG2000:DOC at 56:40:4:4 molar 
ratio. They observed that the optimal Chol content was 40 mol% for their formulation. These 
results are not supported by the findings done in our study. The formulation and preparation 




hydrated their lipid film with PBS and both probe sonicated and extruded their liposomes (Chen 
et al., 2017). 
Yang et al. (2007) made paclitaxel liposomes with SPC:Chol (90:10 lipid molar ratio) and 
SPC:Chol:DSPE-mPEG2000 (90:10:5 lipid molar ratio), and reported an entrapment efficiency 
of 61 and 57 %, respectively. Compared to this study, the SPC:Chol (No. 2) liposomes with 2:1 
molar ratio, has a much higher amount of Chol and a lower EE %. Interestingly, the SPC:DSPE-
PEG2000 (No. 5) liposomal formulation in our study showed an entrapment efficiency of 68 
%, with approximately 14:1 molar ratio of SPC:DSPE-PEG2000. The results might not be 
comparable as Yang et al. (2007) used paclitaxel as investigated drug and a different method 
of preparation, a modified thin-film hydration method where they evaporated solvents and 
flushed the lipid film with nitrogen and under vacuum overnight before hydrating the lipid film 
whit a phosphate buffer saline (PBS), thereafter extruding the dispersion to reduce the size of 
the liposomes (Yang et al., 2007). However, paclitaxel and DOC are both taxanes and are quite 
similar in structure, both highly lipophilic (Louage et al., 2017). It would be interesting to 
investigate the DSPE-PEG2000 further in a lipid combination, as PEGylation have shown 
decreased uptake by the MPS (Kim, 2016; Bozzuto and Molinari, 2015). 
Formulation number 1 (SPC), 6 (SPC:DOTAP) and 10 (SPC:DMPG) shown in Table 12 were 
the most promising liposomal formulations after screening of the different lipids combinations 
in liposomal formulations, as they show an entrapment efficiency near 100 %. 
The SPC:DOTAP formulation (No. 6) showed superior entrapment efficiency. This was the 
only cationic lipid used in the Screening study, and the formulation in this study showed a 
cationic charge at 76.3 mV. The fatty acyl chains of DOTAP, dioleyl is unsaturated with C18 
chains. In comparison with the two other PLs with dioleoyl fatty acids, DOPC and DOPE used 
in this study, the DOTAP liposomal formulation displayed a higher entrapment with 115 % 
relative to DOPE with 83 % and DOPC with 54 %. The structure which separate DOTAP 
(Figure 6) from DOPE and DOPC (Table 1) is the head group which, among other things, does 
not have a phosphorous group. Both DOTAP and DOPC have a trimethylamine in their head 





A study on liposomes with paclitaxel in 3 and 4 mol% with respect to lipid, and DOTAP and 
different phosphatidylcholine in different lipid ratios investigated incorporation effect 
(Campbell et al., 2001). The results indicated a high incorporation of paclitaxel near 100 % 
with increased mol% of DOTAP. The DSPC:DOTAP showed a 100 % incorporation with 3 
mol% paclitaxel and 60 % incorporation with 4 mol% paclitaxel with a 20 mol% of DOTAP. 
Our results with SPC:DOTAP, with approximately 20 mol% DOTAP and 8.5 mol% DOC 
showed an entrapment efficiency near 100 %. They also found that increasing amount of 
DOTAP increases the incorporation of paclitaxel up to a certain point and with some 
exceptions. It must be pointed out that these results are not comparable with our study, as they 
used different lipid compositions, a different drug and other preparation and characterization 
methods (Campbell et al., 2001). 
Yang et al. (2009) reported an entrapment efficiency of 98 % of SPC liposomes containing 
DOC with a 25:1 (w/w) lipid:drug ratio. Although they chose a different preparation method, 
the ethanol injection method, followed by extrusion to obtain liposomes with the targeted size 
range, 100 nm, the lipid composition is similar (Yang et al., 2009). In this study we showed 
that a lipid:drug ratio of 10:1 (w/w) of SPC liposomes was achievable with close to 100 % DOC 
entrapment efficiency (Table 12). Even though we managed to solubilize DOC with a lipid:drug 
ratio of 10:1 (w/w) and achieved a concentration of approximately 2 mg/mL, the commercially 
available DOC formulation in the Norwegian market have a concentration of 20 mg/mL 
(Felleskatalogen, n.d.). Thus, if this were to be the final formulation to be administrated, it 
would most likely require a higher volume of injection to reach therapeutic range.  
The three liposomal formulations with EE near 100 % and a DOC:lipid ratio of approximately 
1:10 (w/w), SPC (No. 1), SPC:DOTAP (No. 6) and SPC:DMPG (No. 10), respectively, were 





5.2.1 Quantification of lipid loss 
The PC-assay examined the amount of phosphorus in the different liposomal dispersions in 
order to give an estimation of lipid concentration (Bartlett, 1959; Naderkhani et al., 2015). The 
results are presented in Table 13. The theoretically concentration of lipid was 20 mg/mL. Since 
Chol, DOTAP, Ceramide C6 and Ceramide C12 does not contain a phosphorous group like the 
other lipids, the amount of these lipids was not quantified, and hence, this was adjusted for in 
calculation. Thus, the expected quantified PL-concentration in these liposomal formulations 
were 16 mg/mL. 





(nm ± SD) 
PL concentration (mg/mL) ± SD PL recovery 
(%) 
Total sample Supernatant 
1  SPC 81.82 ± 3.46 21.26 ± 1.33 18.22 ± 0.24 85.9 ± 0.05 
2  SPC:Chol 59.80 ± 3.26 17.03 ± 0.49 16.57 ± 0.44 97.2 ± 0.04 
3  SPC:DOPE 91.31± 0.55 20.89 ± 0.12 17.62 ± 0.12 84.4 
4  SPC:DOPC 78.11 ± 0.50 22.63 ± 0.29 20.22 ± 0.32 89.3 
5  SPC:DSPE-
PEG2000 
97.55 ± 0.24 18.89 ± 0.06 17.96 ± 0.04 95.1 
6  SPC:DOTAP 77.97 ± 0.25 27.01 ± 0.17 23.98 ± 0.06 88.8 
7  SPC:CC6 77.35 ± 0.52 17.68 ± 0.05 15.87 ± 0.06 89.8 
8  SPC:CC12 96.93 ± 0.83 16.38 ± 0.04 14.64 ± 0.04 89.3 
9  SPC:DPPG 103.67 ±0.71 23.00 ± 0.04 20.86 ± 0.05 90.7 
10  SPC:DMPG 98.69 ± 0.82 22.39 ± 0.07 21.48 ± 0.07 95.9 
11  SPC:DMPC 109.37 ± 0.68 23.04 ± 0.08 19.49 ± 0.08 84.6 
12  SPC:DMPE 182.57 ± 8.98 22.36 ± 0.04 22.18 ± 0.05 99.2 
13  SPC:POPC 81.48 ± 0.26 22.77 ± 0.06 21.84 ± 0.09 95.7 
14  SPC:POPE 86.03 ± 0.93 20.78 ± 0.02 20.24 ± 0.05 97.4 
 
The PL recovery was around 84-99 % which indicate that the loss of lipid during purification 
process with centrifugation was relatively low. The amount of lipid added to the liposomal 
formulations was 20 mg/mL with exception of SPC:Chol, SPC:DOTAP, SPC:Ceramide C6 and 
SPC:Ceramide C12 liposomes in which the amount was 16 mg/mL, and after centrifugation 




recovery. This could be seen with SPC:Chol with small liposome size and high PL recovery, 
compared with several of the other liposomal formulations with bigger size and a slightly lower 
PL recovery, as shown in Table 13.  
Interestingly, the liposomal formulation with the highest PL recovery was the SPC:DMPE, 
which also displayed the biggest liposome size with 182 nm. The SPC:DMPE liposomal 
formulation was made two times, in which the first displayed an average size of 210 nm and a 
PI > 0.9 (data not shown) after two minutes sonication. Therefore, we de decided to make a 
new formulation (No. 12) to target a smaller size which was sonicated for 4 minutes. The 
targeted size was not achieved, and it seemed like this liposomal formulation needed longer 
sonication time to become smaller. Because of low entrapment and limited time for 
optimization, we decided not to make a new sample of this liposomal formulation. The high PL 
recovery of this liposomal formulation needs further investigation, but it could be that the size 
was small enough to be under the cut off line for what was become a part of the pellet, even 





5.3 Optimization study 
This part of the study involved three of the liposomal formulations from the previous Screening 
study, SPC (formulation no 1), SPC:DOTAP (formulation no 6) and SPC:DMPG (formulation 
no 10). In order to see if these formulations could be further optimized, the lipid:drug ratio was 
increased from 10:1 (w/w) used in the Screening study to 10:2 (w/w). The purpose was to see 
if increased amount of DOC could be further solubilized in the liposomes with the same amount 
of lipid.  
The concentration of DOC was doubled compared to the Screening study, from 2 mg/mL to 4 
mg/mL. All formulations contained 200 mg of lipid and 40 mg DOC. The liposomal 
characteristics of the three different formulations are presented in Table 14 and the drug content 
is presented in Table 15.  










(nm ± SD) 
PI 
(AU ± SD) 
Zeta potential 
± SD 
SPC 100 2 min 80.06 ± 0.61 0.28 ± 0.01 -0.45 ± 0.03 
SPC:DOTAP 80:20 1 min 104.47 ± 0.06 0.25 ± 0.01 57.70 ± 0.93 
SPC:DMPG 80:20 0.5 min 106.50 ± 0.10 0.23 ± 0.00 -28.77 ± 0.75 
 
The average diameter of the liposomal formulations shown in Table 14 was around 100 nm, 
which is similar to the average diameter of the same liposomal formulations in the Screening 
study, with exception of SPC:DOTAP which could be explained by a shorter sonication time 
in this Optimization study. The PI value of all three liposomal formulations were < 0.3 which 
indicates that they have a homogenous relatively small width distribution. The zeta potential of 
the SPC was slightly negative as expected and observed in the Screening study. The charge of 
the SPC:DOTAP liposomes were highly positive, and the SPC:DMPG liposomes were 
negatively charged, both as observed in the Screening study. Thus, as expected, increased DOC 










DOC concentration (µg/mL) DOC recovery 
in supernatant 
(%)  
Total sample Supernatant  
SPC 2 min 406.24 ± 6.75 83.82 ± 1.37 21 % 
SPC:DOTAP 1 min 348.70 ± 6.97 151.65 ± 2.93 43 % 
SPC:DMPG 0.5 min 375.70 ± 7.72 74.50 ± 1.61 20 % 
 
The recovery of DOC in the supernatant after centrifugation was 21 %, 43 % and 20 % for SPC, 
SPC:DOTAP and SPC:DMPG, respectively. Compared with formulation 1, 6 and 10 in the 
Screening study, which are the same formulations but with a lipid:drug ratio of 10:1, we can 
see that the drug recovery has decreased dramatically as shown in Figure 20. It might be that 
the increased concentration of precipitated drug in the liposomal dispersion capture more 
liposomes in the pellet. Unfortunately, we did not perform any recovery assessment of PL in 
this part of the study, and thus this theory cannot be confirmed. However, both studies indicate 
the positive effect and superiority of the DOTAP formulation. 
 





Thus, in this third part of the study it was not executed a phospholipid assay. We assumed that 
the recovery of lipids was approximately 100 % based on the results from the Screening study, 
and hence calculated the drug:lipid ratio of the formulations in Table 15 to estimate how much 
DOC that was associated with the liposomes. The results are presented in Figure 21. The results 
were compared with the same formulations in the Screening study, but with different lipid:drug 
ratios: 20:1 and 10:1, respectively.  
For the liposomal formulations with SPC lipid only, we can see that an increasing amount of 
DOC has a negative effect on the drug:lipid ratio. This trend was also seen in the two other 
formulations: SPC:DOTAP and SPC:DMPG, but not in the same extent for SPC:DOTAP 
liposomes, as for the two other liposomal formulations. 
 
Figure 21: Estimated DOC:lipid ratio of the liposomal formulations from the Screening study (blue) and the 
Optimization study (beige). 
 
It is desirable to achieve a high entrapment of DOC, in other words, to achieve the highest 
drug:lipid ratio. The outcome of increasing the drug:lipid ratio is reduced amount of lipid 




cost of production (Straubinger and Balasubramanian, 2005). DOTAP is more expensive than 
other naturally occurring lipids (Sætern et al., 2004). 
In this Optimization study, we investigated if DOC could be further solubilized in the 
liposomes, and from the results, it seemed like a 10:1 (w/w) lipid:drug ratio, used in the 
Screening study, was better for entrapment of DOC. The SPC:DOTAP liposomal formulation 
achieved a higher DOC recovery compared to the SPC and the SPC:DMPG liposomal 






5.4 DOTAP study: the effect of different DOTAP concentration on 
DOC entrapment 
The SPC:DOTAP liposomal formulation showed a superior recovery of DOC compared with 
the other formulations in the third part of the study, the “Optimization study”. DOTAP and 
cationic liposomes are particularly interesting because of the electrostatic attraction between 
the positive particles and negative charged components that covers cells (sulphated 
proteoglycans of glycocalyx) which leads to binding to cells (Steffes et al., 2017). A previous 
study demonstrated that cationic liposomes composed of DOTAP:DOPC:Paclitaxel have 
ability to accumulate in tumour blood vessels and increase antitumoral efficacy (Schmitt-Sody 
et al., 2003). 
Sætern et al. (2004) compared the effect of varying the amount of DOTAP in egg PC:DOTAP 
and Camptothecin liposomes in order to find an optimal content of DOTAP for maximum 
incorporation of the drug. They reported that with increasing amount of DOTAP they reached 
a plateau for incorporation of the drug at approximately 20 mol% DOTAP (Sætern et al., 2004). 
The fourth and final part of the project involved comparison of the effect of varying the 
concentration of DOTAP within SPC:DOTAP liposomes. This part involved making new 
liposomal formulations with DOC, where the amount of DOTAP was tested in increasing 
concentrations. The liposomes were prepared with a thin film-hydration method and sonicated 
for one minute. The liposomal characteristics of the five different formulations is presented in 
Table 16. All formulations contained 200 mg lipid and 30 mg DOC. 
Table 16: Liposomal characteristics of DOC:SPC:DOTAP liposomes. 
Liposomal 
formulation 
(DOTAP % (w/w)  
of total lipid) 
Lipid composition  
(lipid ratio w/w) 
Average 
diameter 





1 (0 %) SPC 98.10 ± 0.40 0.22 ± 0.01 -0.92 ± 0.39 
2 (10 %) SPC:DOTAP (9:1) 106.55 ± 0.72 0.27 ± 0.01 54.93 ± 1.75 
3 (20 %) SPC:DOTAP (8:2) 102.28 ± 0.53 0.26 ± 0.01 51.80 ± 1.57 
4 (30 %) SPC:DOTAP (7:3) 102.05 ± 0.47 0.23 ± 0.01 57.58 ± 1.74 





Since sonication processing of SPC:DOTAP liposomal formulations in part 3, the 
“Optimization study”, gave satisfactory size and PI, we decided to sonicate all the formulations 
for 1 minute. The average diameter was around 100 nm for all five liposomal formulations. 
Formulation 1 was composed of 100 % SPC. Formulation 2-5 were composed of increasing 
amount of DOTAP, from 10-50 % (w/w). It seemed like the average diameter decreased slightly 
with increasing amount of DOTAP. 
The PI value of all five liposomal formulations were < 0.3. The zeta potential of formulation 1 
(SPC) was slightly negative, as expected since the PC head group are neutral (Kraft et al., 
2014). Formulation 2-5 all showed a highly positive charge, as expected based on previously 
results and the fact that DOTAP is a cationic lipid (Zhi et al., 2018). 
The five different liposomal formulations were characterized with measurement of 
concentration before and after purification using centrifugation, as shown in Table 17. 
Table 17: Drug content in the liposomal formulations with increasing amount of DOTAP. 
Liposomal formulation 
(DOTAP % (w/w)  
of total lipid) 
Docetaxel concentration (µg/mL) DOC recovery 
in supernatant 
(%) 
Total sample Supernatant  
1 (0 %) 298.19 ± 9.42 79.30 ± 1.14 27 
2 (10 %) 305.18 ± 2.86 166.67 ± 5.32 55 
3 (20 %) 318.92 ± 2.76 154.22 ± 1.34 48 
4 (30 %) 317.23 ± 6.38 168.75 ± 1.38 53 
5 (40 %) 282.83 ± 4.48 218.24 ± 5.73 77 
 
The recovery of formulation 1, the one liposomal formulation only composed of SPC was quite 
poor with only 27 % DOC left in purified sample, as shown in Figure 22. This is interestingly 
since the DOC recovery of the SPC liposomal formulation with a 10:1 (w/w) DOC:lipid ratio 
from the “Screening study”, shown in Table 12, was 95 %. It could seem like an optimal 
DOC:lipid ratio for SPC liposomes was 10:1 (w/w), as the DOC recovery for both SPC 
liposomes in this DOTAP-study, with a 10:1.5 (w/w) DOC:lipid ratio (Table 17), and in the 





Formulation 2-5 composed of SPC:DOTAP with increasing amount of DOTAP showed a 
recovery of DOC between 48 and 77 % as shown in Figure 22. 
 
Figure 22: DOC recovery of the five different liposomal formulations in the DOTAP study. 
 
The highest recovery of DOC was at 50 % (w/w) (~50 mol%). There seem to be a trend that an 
increasing amount of DOTAP solubilize more DOC, although the recovery of formulation 3 
and 4 was slightly lower than formulation 2. Compared to Sætern et al. (2004), it seems like 
we did not achieve an optimal DOTAP content for maximum incorporation of DOC (Sætern et 
al., 2004). It could be discussed that even more DOTAP content would solubilize even more 
DOC, but this needs further investigation. 
In this part of the study we did not perform any recovery assessment of PL. The DOC recovery 
of the five liposomal formulations was varying, and it might be that the DOC concentration was 
too high, hence precipitated in the liposomal dispersion, and thereby the precipitated drug 
captured more liposome in the pellet under centrifugation. Since we did not perform any 
recovery assessment of PL, this cannot be confirmed but needs further investigation. 
Formulation 3 (SPC:DOTAP) from this DOTAP study had a lipid ratio of 80:20 (w/w) with a 











































shown in Table 12, with a DOC:lipid ratio of 10:1 showed a recovery of DOC near 100 %. The 
SPC:DOTAP liposomal formulation from the “Optimization study”, shown in Table 15, with a 
DOC:lipid ratio of 5:1 (w/w) showed a DOC recovery of 43 %. It could seem like the optimal 










The present research work focused on the effect of lipid composition on the DOC entrapment. 
We established a small scale screening method for preparing DOC-liposomes and for separating 
the unentrapped DOC from the liposomes in order to determine the DOC entrapment efficiency.  
In the Pilot project, we established the method used throughout the whole laboratory experiment 
period. In the screening study, 14 different liposomal formulations with different lipid 
compositions were prepared to investigate how the lipid compositions affected the DOC 
entrapment efficiency. Different DOC entrapment values, in the range between 18 and 115 % 
were obtained. No correlation between lipid saturation and DOC entrapment efficiency was 
observed. 
However, three of the liposomal formulations showed entrapment efficiency near 100 %, with 
110, 115 and 95 % for SPC, SPC:DOTAP and SPC:DMPG liposomal formulations, 
respectively. These formulations were brought to the Optimization study to investigate if even 
more DOC could be entrapped in the liposomes. The results showed that a 10:1 (w/w) lipid:drug 
ratio gave better entrapment efficiency than a 10:2 (w/w) lipid:drug ratio. The only cationic 
liposomal formulation in this project, SPC:DOTAP, showed the best entrapment efficiency and 
was further investigated with varying the concentration of the positively charged lipid, DOTAP, 
to see if the DOTAP concentration affected the DOC entrapment. Our results indicate that an 











The results of this thesis represent a preliminary Pilot project and the development of liposomal 
formulation of DOC is only in its infancy. The SPC:DOTAP liposomes with DOC should be 
further explored. The formulation should be further investigated to evaluate its stability, and 
potential to be prepared sterile. Moreover, its stability in biological fluids should be confirmed. 
Short-term perspective 
• Deeper insight and further investigation on solubilizing DOC in the liposomal 
formulation. 
• Investigate if a smaller amount of Chol could contribute to a better entrapment 
efficiency. 
• Run more parallels of SPC and SPC:DOTAP to see if the results are reproducible and 
perform PC-assay to evaluate entrapment efficiency and drug load capacity accurately. 
• Evaluate other methods such as dual asymmetric centrifugation (DAC) as a processing 
method for preparing liposomes. 
• Evaluate the of stability of the liposomal formulation. 
• Evaluate in vitro efficacy (in cytotoxicity assays using human cell lines). 
Long-term perspective 
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